InvestorsHub Logo

EOT

Followers 115
Posts 12461
Boards Moderated 0
Alias Born 05/05/2014

EOT

Re: mrinvestor08 post# 3607

Tuesday, 01/16/2024 6:08:23 PM

Tuesday, January 16, 2024 6:08:23 PM

Post# of 3753
He seems like more of a facilitator to align big pharma deals than anything else. That’s his experience anyway….


“and have been instrumental in establishing more than 40 collaborations and co-operative agreements with major pharmaceutical and biotech companies, “


“I have over 30 years’ experience in the multinational pharmaceutical and biotechnology industries spanning senior roles in Research and Development, Marketing, Sales and Strategic Planning, including managerial positions with Sanofi-Aventis, GlaxoSmithKline, DuPont-Merck Pharmaceuticals, Gemini Genomics Inc. and Locus Pharmaceuticals Inc. Key positions held include: Head of Marketing and Sales, Vice President, Marketing and Business Development, and Chief Business Officer. I was also previously CEO of Nuevolution A/S based in Copenhagen, Denmark (acquired by Amgen) and CEO of Marillion Pharmaceuticals Inc. Presently I serve as Executive Chairman of Eppin Pharma Inc and CEO of Aestas Pharma Inc, both emerging biopharmaceutical companies. I have also raised over $50MM from venture capital firms to fund biotechnology enterprises, and have been instrumental in establishing more than 40 collaborations and co-operative agreements with major pharmaceutical and biotech companies, including licensing, co-marketing and acquisition transactions valued in excess of $600MM. Other career highlights include the successful launches of "blockbuster" drugs, including Imitrex®, Celexa®, Prinivil®/Zestril®, Sinemet CR® and Viazem®/Tiazac®, and the successful $100 MM IPO of Gemini Genomics Inc. and it's subsequent $220MM sale to Sequenom Inc.“
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ATRX News